BMO Capital analyst Gary Nachman lowered the price target on Viatris (NASDAQ: VTRS) to $19.00 (from $23.00) while maintaining an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

Viatris (VTRS) PT Lowered to $15 at JPMorganMarch 1, 2022 7:04 AM Raymond James Downgrades Viatris (VTRS) to Market PerformMarch 1, 2022 6:55 AM BofA Securities Downgrades Viatris (VTRS) to NeutralMarch 1, 2022 6:02 AM Form 8-K Viatris Inc For: Feb 27February 28, 2022 4:58 PM Form 10-K Viatris Inc For: Dec 31February 28, 2022 4:27 PM Viatris (VTRS) PT Lowered to $10 at CowenFebruary 28, 2022 12:16 PM Biocon Biologics to Acquire Viatris' (VTRS) Biosimilars Assets for up to $3.335 billion in Stock and CashFebruary 28, 2022 8:42 AM Biocon Biologics to Acquire Viatris' Biosimilars Assets for up to USD 3.335 billion in Stock and CashFebruary 28, 2022 8:41 AM Form 8-K Viatris Inc For: Feb 28February 28, 2022 8:24 AM Viatris Inc (VTRS) Reports Q4 Adjusted Net Earnings of $971MFebruary 28, 2022 6:09 AM Viatris Reports Strong Fourth Quarter and Full-Year 2021 Financial Results; Issues 2022 Financial Guidance; Completes Comprehensive Strategic Review; Unveils Plan to Reshape the Company for the FutureFebruary 28, 2022 6:00 AM